Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Leukemia 2Recurrence 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Cytarabine 561Azacitidine 385venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 155Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 73Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × sapacitabine × Clear all
NCT00590187 2024-06-04

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Cyclacel Pharmaceuticals, Inc.

Phase 2 Completed
105 enrolled 11 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01303796 2022-06-22

SEAMLESS

Cyclacel Pharmaceuticals, Inc.

Phase 3 Completed
482 enrolled 24 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01211457 2019-07-16

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Cyclacel Pharmaceuticals, Inc.

Phase 1/2 Unknown
65 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡